In particular, the radiopharmaceutical 68Ga-PSMA-HBED-CC, namely 68Ga-PSMA-11, proved useful for the in vivo imaging of prostate cancer and its metastatic localizations [78] and has been recently approved by FDA (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf, accessed on 8 March 2021). Here, FOLH1 is linked to prostate cancer.